
Anemia and iron deficiency are linked to higher odds of acute heart failure during pregnancy and after childbirth, according to a study.

Anemia and iron deficiency are linked to higher odds of acute heart failure during pregnancy and after childbirth, according to a study.

Among 821,327 outpatients, cystatin C–based eGFR at least 30% below creatinine-based eGFR was linked to higher death and heart failure rates.

An employer coalition's new guide outlines how workplaces can prevent and manage diabetes, from benefit design to accommodations.

Obinutuzumab (Gazyva) led to complete remission of proteinuria in more patients than tacrolimus did, according to the FDA.

New ACACIA-HCM analyses at HCMS 2026 add imaging and quality-of-life data as Cytokinetics readies an FDA filing in nonobstructive HCM.

An oral SERD plus everolimus cut the risk of progression or death by 62% in ESR1-mutated advanced breast cancer.

The updated label now includes phase 3 data comparing aficamten monotherapy with metoprolol in adults with symptomatic obstructive HCM.

Once weekly tirzepatide significantly reduces body mass index in adolescents with obesity compared with placebo.

Rural patients with HFrEF had lower mortality when treated at urban hospitals but higher early mortality than urban patients at those hospitals.

Report urges payment reform, food policy changes, and wider treatment access, warning that drugs alone can't fix obesity's root causes.

Once weekly ribupatide, a dual GIP/GLP-1 receptor agonist, led to significantly greater weight loss than placebo at 48 weeks, according to a study.

Mike Sharma, MD, discusses early efficacy signals, long-term stroke risk, patient impact, and why antithrombotic treatment should be tailored to each condition.

Research at ObesityWeek 2026 tracks rising obesity in Medicare, productivity losses, prior authorization denials, and GLP-1 persistence.

Protein intake below 0.6 g/kg/d was linked to a higher risk of kidney failure and death, according to a Korean cohort study.

Mike Sharma, MD, discusses the asundexian trial’s broad patient population, results across stroke subtypes, and bleeding outcomes.

In this Q&A, Christie Ballantyne, MD, explains why consistent LDL-C lowering with oral enlicitide could expand PCSK9 use in primary prevention.

Independent VESALIUS-CV analysis finds evolocumab cost-effective at about 36% below the ACC/AHA benchmark for patients without prior MI or stroke.

A new tool puts this year's measles toll at nearly $83 million as global health experts weigh whether the US has lost elimination status.

In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.

Biykem Bozkurt, MD, PhD, explains why survodutide, a glucagon and GLP-1 dual agonist, needed a cardiovascular safety trial in patients with obesity.

SCOUT-HCM 56-week data show sustained LVOT gradient reductions with mavacamten and no LVEF below 50% in adolescents with obstructive HCM.

New analyses from VESALIUS-CV and the FOURIER open-label extension add stroke and long-term outcome data for evolocumab.

The glucagon/GLP-1 dual agonist is noninferior to placebo for major adverse cardiovascular events and lowers blood pressure and waist size.

With the midterms behind them, health system leaders say coverage losses, thin margins, and payer fights are coming no matter who controls Congress.

In a matched analysis of Epic COSMOS records, acoramidis was tied to an 18% lower composite risk and about 25% lower hospitalization risk.

A runner's death at the NYC marathon highlights how heat, dehydration, illness, drugs, and genetics can raise exertional rhabdomyolysis risk.

Rural residents with HFrEF got more specialty care and therapy at urban hospitals but still had higher early mortality than urban patients there.

The planned separation would keep Aetna, CVS Caremark, and Oak Street Health together and move roughly 9000 drugstores into a new CVS Pharmacy.

Many patients who stop a GLP-1 RA regain weight. How plans can measure adherence when cash-pay fills go unseen.

In more than 250,000 adults with prediabetes and obesity, GLP-1 users had lower risks of type 2 diabetes, death, and cardiovascular events.

August 21st 2025

December 21st 2022

December 12th 2024

Published: July 18th 2024 | Updated: July 18th 2024